Advanced Filters
noise

One or multiple investigational sites, Luxembourg Clinical Trials

A listing of One or multiple investigational sites, Luxembourg clinical trials actively recruiting patients volunteers.

Found 62,997 clinical trials
E Eugenio Mercuri

Natural History of SMA

This is an investigator initiated observational study with the aim to record several aspects of function, care and adverse events in a large cohort of SMA patients followed longitudinally by using a structured academic disease registry.

years of age All Phase N/A
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Genetics of Inherited Eye Disease

Background Research has identified some of the genes involved in inherited eye diseases. But for many of these diseases, the genes are not yet known. Researchers want to try to find these genes. They also hope to learn more about how symptoms differ in people with similar gene changes. Objective …

1 - 120 years of age All Phase N/A
X Xiao Xiao

Autoimmune Hepatitis Cohort in China

The goal of this observational study is to describe the clinical features and long-term prognosis in patients diagnosed with autoimmune hepatitis (AIH) in China and assess the effectiveness and safety of AIH treatment options in a real-world setting.

14 years of age All Phase N/A
D Dongling Zou, M.D.

Comparing the Efficacy of Surgery Staging and Image Staging of Locally Advanced Cervical Cancer

The study is a domestic multicenter, prospective, non-randomized controlled concurrent trial. It will be assessed whether surgery staging on locally advanced cervical cancer is superior to image staging for improving progression-free survival and overall survival.

18 - 75 years of age Female Phase N/A

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).

18 years of age All Phase 2
J Jessica Moe, MD

Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments

This is a multi-centre, open-label RCT at four Emergency Departments (EDs) in British Columbia and Alberta. The purpose of the current study is to compare the effectiveness of buprenorphine/naloxone microdosing and standard dosing take-home induction regimens at enabling patients to successfully complete the induction regimen, and at retaining patients on …

18 years of age All Phase 2/3
Z Zhi-Liang Gao, Professor

Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

There are about 400 million chronic hepatitis B virus (HBV) infection patients worldwide, posing a serious threat to global public health security. In China, HBV infection occured mainly in the perinatal period or infants, and about 10% of patients in the immune tolerance stage spontaneously transit to the immune clearance …

18 - 60 years of age All Phase 4
D Dafne Balemans, MSc

Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)

Aim More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.

18 - 65 years of age All Phase N/A

International Registry Study of Neutral Lipid Storage Disease (NLSD) / Triglyceride Deposit Cardiomyovasculopathy (TGCV) and Related Diseases

This study aims to understand the state of onset of NLSD(neutral lipid storage disease) / TGCV(triglyceride deposit cardiovasculopathy) worldwide, background information of affected patients, and natural history of the disease, as well as exploring the prognostic factors and assessing the efficacy of disease-specific treatment.

years of age All Phase N/A
A Ann Gandolfi

Value of Analysing Under-utilised Leftover Tissue (VauLT)

Intratumour heterogeneity is well recognized in multiple cancer types and ultimately leads to therapeutic resistance. It also limits the ability of small samples to represent the whole tumour, having implications for diagnosis, molecular analysis and understanding of the tumour immune microenvironment. By blending- 'homogenizing'- leftover tumour tissue in excess of …

18 years of age All Phase N/A

Simplify language using AI